Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v4-FR Version v2-FR
Language French French
Date Updated 2021-01-26 2020-09-17
Drug Identification Number 02486628 02486628
Brand name SODIUM BICARBONATE INJECTION, USP SODIUM BICARBONATE INJECTION, USP
Common or Proper name Sodium Bicarbonate Injection Sodium Bicarbonate Injection
Company Name FRESENIUS KABI CANADA LTD FRESENIUS KABI CANADA LTD
Ingredients SODIUM BICARBONATE SODIUM BICARBONATE
Strength(s) 42MG 42MG
Dosage form(s) SOLUTION SOLUTION
Route of administration INTRAVENOUS INTRAVENOUS INTRAVENOUS INTRAVENOUS
Packaging size 4.2%, 2.5 mEq (mmol), 5 mL Vial 4.2%, 2.5 mEq (mmol), 5 mL Vial
ATC code B05XA B05XA
ATC description I.V. SOLUTION ADDITIVES I.V. SOLUTION ADDITIVES
Reason for shortage Disruption of the manufacture of the drug. Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2020-09-15 2020-09-15
Estimated end date Unknown Unknown
Actual end date 2020-12-05
Shortage status Resolved Actual shortage
Tier 3 Status No No
Company comments Fresenius Kabi Canada Ltd. regrets to advise that due to unforeseen circumstances, our Sodium Bicarbonate Injection, USP, 4.2%, 2.5 mEq (mmol), 5 mL Vial is on backorder, effective today. We are working with our production site to expedite receipt of our next shipment. UPDATE Available 12/05/2020 Fresenius Kabi Canada Ltd. regrets to advise that due to unforeseen circumstances, our Sodium Bicarbonate Injection, USP, 4.2%, 2.5 mEq (mmol), 5 mL Vial is on backorder, effective today. We are working with our production site to expedite receipt of our next shipment.
Health Canada comments